KR950703942A - 아토바큐온 약학적 조성물(atovauone pharmaceutical compositions) - Google Patents

아토바큐온 약학적 조성물(atovauone pharmaceutical compositions) Download PDF

Info

Publication number
KR950703942A
KR950703942A KR1019950702217A KR19950702217A KR950703942A KR 950703942 A KR950703942 A KR 950703942A KR 1019950702217 A KR1019950702217 A KR 1019950702217A KR 19950702217 A KR19950702217 A KR 19950702217A KR 950703942 A KR950703942 A KR 950703942A
Authority
KR
South Korea
Prior art keywords
particles
pharmaceutical composition
mixture
microfluidized
pharmaceutically acceptable
Prior art date
Application number
KR1019950702217A
Other languages
English (en)
Other versions
KR0175193B1 (ko
Inventor
로이 던 앨런
Original Assignee
엠. 가렛
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠. 가렛, 더 웰컴 파운데이션 리미티드 filed Critical 엠. 가렛
Publication of KR950703942A publication Critical patent/KR950703942A/ko
Application granted granted Critical
Publication of KR0175193B1 publication Critical patent/KR0175193B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fertilizers (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 마이크로 유동화된 아토바큐온 입자 및 그 제조 방법에 관한것이다. 더 구체적으로 본 발명은 개선된 생체적합성 및 치료 용도를 갖는 마이크로 유동화된 아토바큐온 입자를 함유하는 약학적 조성물에 관한 것이다.

Description

아토바큐온 약학적 조성물(ATOVAUONE PHARMACEUTICAL COMPOSITIONS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 입자의 95% 이상이 0.1-2㎛ 범위의 부피 직경을 갖는 입자 형태의 아토바큐온.
  2. 마이크로 유동화된 아토바큐온 입자.
  3. 입자의 95% 이상이 0.1-2㎛ 범위의 부피 직경을 갖는 마이크로유동화된 아토바큐온 입자.
  4. 아토바큐온 입자 및 그것에 대한 한개 이상의 약학적 허용 담체를 포함하며 입자의 95% 이상이 0.1-2㎛범위의 부피 직경을 갖는 약학적 조성물.
  5. 제4항에 있어서, 입자가 마이크로 유동화된 입자의 약학적 조성물.
  6. 제4항 또는 제5항에 있어서, 서스펜션 형태인 약학적 조성물.
  7. 제4항 내지 제6항중 어느 한 한에 있어서, 약학적 허용 담체가 현탁제를 포함하는 약학적 조성물.
  8. 제7항에 있어서, 상기 현탁제가 크산탄 검인 약학적 조성물.
  9. 제4항 내지 제8항중 어느 한 항에 있어서, 치료에 유용한 약학적 조성물.
  10. 제4항 내지 제8항중 어느 한 항에 있어서, 원생 동물성 기생출 감염 및 피. 카리니(P. carinii)에 의한 감염의 치료 및/또는 예방에 유용한 약학적 조성물.
  11. 아토바큐온을 액체 부형제와 혼합하여 450mg/mL 이하의 아토바큐온 농도를 갖는 혼합물을 준비하고, 상기 혼합물을 마이크로 유동기에 3회 이상 통과시키는 단계를 포함하여 제2항 또는 제3항의 마이크로 유동화된 아토바큐온 입자를 제조하는 방법.
  12. 하기 (a) 내지 (c) 단계들을 포함하는 약학적 조성물의 제조 방법; (a) 아토바큐온을 액체 부형제와 혼합하여 아토바큐온 농도가 450mg/mL 이하인 혼합물을 준비하는 단계, (b) 그 혼합물을 마이크로 유동화시키기 위해 마이크로 유동기에 3회 이상 통과시키는 단계(이때, 아토바큐온은 입자의 형태이며 그 입자의 95% 이상이 0.1-2㎛ 범위의 부피 직경을 갖는다), (c) 마이크로 유동화된 제조물을 그것에 대한 한개 이상의 약학적 허용담체와 혼합하는 단계.
  13. 제11항 또는 제12항에 있어서, 상기 혼합물을 마이크로 유동기에 20 내지 50회 통과시키는 방법.
  14. 제13항에 있어서, 상기 혼합물을 마이크로 유동기에 15-25회 통과시키는 방법.
  15. 제11항 내지 제14항중 어느 한 항에 있어서, 사이 액체 부형제가 계면활성제 용액인 방법.
  16. 제15항에 있어서, 상기 계면활성제 용액이 폴록사머(Poloxamer) 188 용액인 방법.
  17. 제12항에 있어서, 상기 약학적 허용 담체가 현탁제를 포함하는 방법.
  18. 제17항에 있어서, 상기 현탁제가 크산탄 검인 방법.
  19. 제12항 내지 제18항중 어느 한 항의 방법에 의해 제조된 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702217A 1992-12-24 1993-12-23 아토바큐온 함유 약학 조성물 KR0175193B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929226905A GB9226905D0 (en) 1992-12-24 1992-12-24 Pharmaceutical preparation
GB9226905.9 1992-12-24
PCT/GB1993/002646 WO1994014426A1 (en) 1992-12-24 1993-12-23 Atovaquone pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR950703942A true KR950703942A (ko) 1995-11-17
KR0175193B1 KR0175193B1 (ko) 1999-02-01

Family

ID=10727175

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702217A KR0175193B1 (ko) 1992-12-24 1993-12-23 아토바큐온 함유 약학 조성물

Country Status (36)

Country Link
US (2) US6018080A (ko)
EP (1) EP0675711B1 (ko)
JP (1) JP3461353B2 (ko)
KR (1) KR0175193B1 (ko)
CN (1) CN1076194C (ko)
AT (1) ATE169215T1 (ko)
AU (2) AU675102B2 (ko)
BG (1) BG61932B1 (ko)
BR (1) BR9307719A (ko)
CA (1) CA2152615C (ko)
CZ (1) CZ289701B6 (ko)
DE (1) DE69320208T2 (ko)
DK (1) DK0675711T3 (ko)
ES (1) ES2122223T3 (ko)
FI (1) FI114007B (ko)
GB (1) GB9226905D0 (ko)
GE (1) GEP19991515B (ko)
HK (1) HK1004086A1 (ko)
HR (1) HRP931516B1 (ko)
HU (1) HU220215B (ko)
IL (1) IL108154A (ko)
MY (1) MY109990A (ko)
NO (1) NO316745B1 (ko)
NZ (1) NZ258995A (ko)
PL (1) PL175374B1 (ko)
RO (1) RO119686B1 (ko)
RU (1) RU2127585C1 (ko)
SA (1) SA94140644B1 (ko)
SG (1) SG43901A1 (ko)
SI (1) SI9300678A (ko)
SK (1) SK281924B6 (ko)
TW (2) TW514531B (ko)
UA (1) UA39879C2 (ko)
WO (1) WO1994014426A1 (ko)
YU (1) YU48919B (ko)
ZA (1) ZA939673B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
AU753278B2 (en) * 1998-02-25 2002-10-10 Abbott Laboratories Butorphanol sustained release formulations
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US7183518B2 (en) * 2004-09-24 2007-02-27 Michael Near System of food storage preparation and delivery in finished cooked state
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
JP5080445B2 (ja) * 2005-04-13 2012-11-21 アボット ゲーエムベーハー ウント コー． カーゲー 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用
US20080241254A1 (en) * 2007-01-02 2008-10-02 Suryakant Navale Pharmaceutical composition comprising atovaquone particles
DE102007001473A1 (de) 2007-01-08 2008-07-10 Andreas Lemke Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
WO2009007991A2 (en) * 2007-04-19 2009-01-15 Ipca Laboratories Limited A new process for preparation of atovaquone and novel intermediates thereof
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
US20100099776A1 (en) * 2008-10-20 2010-04-22 Ranbaxy Laboratories Limited Oily suspension of atovaquone
WO2011021230A2 (en) 2009-08-20 2011-02-24 Ipca Laboratories Limited Novel complex for treatment and/or prophylaxis of parasitic infections
MX337893B (es) * 2009-11-10 2016-03-28 Celgene Corp Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion.
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
EP2934484A1 (en) 2012-12-19 2015-10-28 Kashiv Pharma, LLC Supersaturated stabilized nanoparticles for poorly soluble drugs
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3471697A1 (en) * 2016-06-16 2019-04-24 The University of Liverpool Chemical composition
US20220265566A1 (en) * 2018-10-18 2022-08-25 Tulex Pharmaceuticals Inc. Atovaquone nanoparticulate compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
NL6411993A (ko) * 1963-10-18 1965-04-20
US3347830A (en) * 1964-07-30 1967-10-17 Grace W R & Co Process of polymerizing formaldehyde
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE2601458A1 (de) * 1975-01-20 1976-07-22 Ciba Geigy Ag Loesliche, von phenylindandiaminen abgeleitete polyamide
EG14152A (en) * 1977-11-22 1983-12-31 Wellcome Found Antitheilerial naphtoquinone derivatives
US4485117A (en) 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
DE3141691A1 (de) * 1981-10-21 1983-05-19 Hoechst Ag, 6230 Frankfurt Plasmid pac 1, verfahren zu seiner gewinnung und seine verwendung
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
US5175319A (en) 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
PL276385A1 (en) * 1987-01-30 1989-07-24 Exxon Chemical Patents Inc Method for polymerization of olefines,diolefins and acetylene unsaturated compounds
IL85097A (en) * 1987-01-30 1992-02-16 Exxon Chemical Patents Inc Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes
US4783389A (en) * 1987-03-27 1988-11-08 E. I. Du Pont De Nemours And Company Process for preparation of liquid electrostatic developers
US5155080A (en) * 1988-07-15 1992-10-13 Fina Technology, Inc. Process and catalyst for producing syndiotactic polyolefins
US5225500A (en) * 1988-07-15 1993-07-06 Fina Technology, Inc. Process and catalyst for producing syndiotactic polyolefins
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
US5225184A (en) * 1988-08-16 1993-07-06 Burroughs Wellcome Co. Medicaments
DE68928964T2 (de) * 1988-08-16 1999-07-29 Wellcome Found Neue Naphthochinone und ihre Anwendung als Arzneimittel
KR930002411B1 (ko) * 1988-09-14 1993-03-30 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 벤젠불용성 유기알루미늄 옥시화합물 및 그 제조방법
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
CA2027145C (en) * 1989-10-10 2002-12-10 Michael J. Elder Metallocene catalysts with lewis acids and aluminum alkyls
GB8923254D0 (en) * 1989-10-16 1989-12-06 Wellcome Found Medicaments
CA2027122C (en) * 1989-10-30 2002-12-10 John A. Ewen Making metallocene catalysts using aluminum alkyls for controlled polymerization of olefins
US5387568A (en) * 1989-10-30 1995-02-07 Fina Technology, Inc. Preparation of metallocene catalysts for polymerization of olefins
DE3942363A1 (de) * 1989-12-21 1991-06-27 Hoechst Ag Verfahren zur herstellung einer polypropylen-formmasse
JP2545006B2 (ja) * 1990-07-03 1996-10-16 ザ ダウ ケミカル カンパニー 付加重合触媒
JP3076619B2 (ja) 1991-05-14 2000-08-14 三井化学株式会社 ブロック共重合体の製造方法
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5766522A (en) * 1996-07-19 1998-06-16 Morton International, Inc. Continuous processing of powder coating compositions
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5914135A (en) * 1997-04-16 1999-06-22 Mcneil-Ppc, Inc. Liquid antacid compositions

Also Published As

Publication number Publication date
CA2152615C (en) 2001-10-16
AU696662B2 (en) 1998-09-17
US6649659B1 (en) 2003-11-18
NZ258995A (en) 1997-01-29
PL309629A1 (en) 1995-10-30
TW514531B (en) 2002-12-21
RO119686B1 (ro) 2005-02-28
NO952522L (no) 1995-06-22
CN1076194C (zh) 2001-12-19
HRP931516A2 (en) 1995-10-31
DE69320208T2 (de) 1999-01-21
SK281924B6 (sk) 2001-09-11
FI114007B (fi) 2004-07-30
DK0675711T3 (da) 1999-05-03
JP3461353B2 (ja) 2003-10-27
AU1627997A (en) 1997-05-22
EP0675711B1 (en) 1998-08-05
NO952522D0 (no) 1995-06-22
HRP931516B1 (en) 1999-04-30
UA39879C2 (uk) 2001-07-16
HU9501812D0 (en) 1995-08-28
ES2122223T3 (es) 1998-12-16
HUT71528A (en) 1995-12-28
FI953139A (fi) 1995-06-22
WO1994014426A1 (en) 1994-07-07
SI9300678A (en) 1994-09-30
ZA939673B (en) 1995-06-23
AU5710594A (en) 1994-07-19
BG99723A (bg) 1996-01-31
MY109990A (en) 1997-10-31
CA2152615A1 (en) 1994-07-07
HK1004086A1 (en) 1998-11-13
BG61932B1 (bg) 1998-10-30
HU220215B (hu) 2001-11-28
ATE169215T1 (de) 1998-08-15
CZ289701B6 (cs) 2002-03-13
KR0175193B1 (ko) 1999-02-01
SK82895A3 (en) 1995-11-08
YU80893A (sh) 1997-03-07
FI953139A0 (fi) 1995-06-22
US6018080A (en) 2000-01-25
IL108154A0 (en) 1994-04-12
CN1103290A (zh) 1995-06-07
SG43901A1 (en) 1997-11-14
DE69320208D1 (de) 1998-09-10
JPH08504805A (ja) 1996-05-28
PL175374B1 (pl) 1998-12-31
AU675102B2 (en) 1997-01-23
GB9226905D0 (en) 1993-02-17
IL108154A (en) 2000-02-17
EP0675711A1 (en) 1995-10-11
GEP19991515B (en) 1999-03-05
RU2127585C1 (ru) 1999-03-20
NO316745B1 (no) 2004-04-26
SA94140644B1 (ar) 2005-06-14
CZ145195A3 (en) 1995-10-18
YU48919B (sh) 2002-11-15
BR9307719A (pt) 1999-08-31
TW443935B (en) 2001-07-01

Similar Documents

Publication Publication Date Title
KR950703942A (ko) 아토바큐온 약학적 조성물(atovauone pharmaceutical compositions)
RU95122758A (ru) Атовакон в форме частиц, микропсевдоожиженные частицы атовакона, фармацевтическая композиция, содержащая частицы атовакона, и способ ее получения
US4913908A (en) Preparation of submicroscopic particles, particles thus obtained and pharmaceutical compositions containing them
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
EP1786841B1 (en) Ultrasound-assisted synthesis of cyclodextrin-based nanosponges
BRPI0206509A8 (pt) Processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
DK0608207T3 (da) Farmaceutiske præparater med indhold af nanokapsler
CA2512487A1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR960033470A (ko) 정맥내 투여용 나노현탁액
JPS6191131A (ja) 医薬品の吸着防止方法および組成物
BR9909189A (pt) Suspensão de agente ativo peroral
de Moura Ferraz et al. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole
US6028065A (en) Flocculated suspension of megestrol acetate
TH10612B (th) สารผสมทางเภสัชกรรมแอโทวาโควน
TH14776A (th) สารผสมทางเภสัชกรรมแอโทวาโควน
US5385890A (en) Antithrombin III preparation
CA2486571C (en) Pharmaceutical composition
JPH07506352A (ja) フラビウイルス感染の治療におけるヘテロポリタングステン酸塩
JP2021506905A (ja) 血液中のＣａｎｄｉｄａ ａｕｒｉｓを処置するための方法および医薬組成物
JPS6396121A (ja) レーシュマニア症治療剤
FR2614890B1 (fr) Compose resultant du couplage d'une molecule a structure chimiosensibilisante et d'une molecule a structure cytotoxique, procede de preparation, application a titre de medicament et compositions pharmaceutiques le contenant
Veenhoven et al. Bacterial infections and thrombocytopenia in chronic idiopathic thrombocytopenic purpura
Yutaka et al. Preparation and Release Characteristics of Cisplatin Albumin Microspheres Containing Chitin and Treated with Chitosan
Aramwit Effect of gamma-irradiation on in-vitro plasmacompatibility of nanosuspension formulation
JP2006241028A5 (ko)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111028

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee